Modotuximab Biosimilar - Research Grade

Human

EGFR

>1mg/ml

IgG1 - kappa

CHO Cells

Bulk Anti-Human EGFR (EGFR.1) Antibody (ICH1021), Cetuximab Biosimilar - Research Grade (ICH4004), Matuzumab Biosimilar - Research Grade (ICH4007), Nimotuzumab Biosimilar - Research Grade (ICH4008), Panitumumab Biosimilar - Research Grade (ICH4028), Zalutumumab Biosimilar - Research Grade (ICH5116), Necitumumab Biosimilar - Research Grade (ICH5121), Depatuxizumab Biosimilar - Research Grade (ICH5294), Becotatug Biosimilar - Research Grade (ICH5378), Demupitamab Biosimilar - Research Grade (ICH5473), Futuximab Biosimilar - Research Grade (ICH5560), Imgatuzumab Biosimilar - Research Grade (ICH5600), Laprituximab Biosimilar - Research Grade (ICH5626), Losatuxizumab Biosimilar - Research Grade (ICH5657), Pimurutamab Biosimilar - Research Grade (ICH5774), Serclutamab Biosimilar - Research Grade (ICH5853), Tomuzotuximab Biosimilar - Research Grade (ICH5933)

https://www.imgt.org/mAb-DB/

ICH3002

P00533

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-EGFR antibody modotuximab, supplied for research use only. It is a full-length human IgG1/kappa molecule engineered to recognize the human epidermal growth factor receptor (EGFR/ErbB1, UniProt P00533), providing a defined, reproducible reagent for studying EGFR biology without the regulatory and cost constraints of a clinical drug. Because it reproduces the binding specificity of the originator while being produced as a bulk research material, it is well suited to in-vitro and preclinical work: receptor-binding and blocking assays, competition and epitope-mapping studies, flow cytometry and immunoassay development, and as an isotype-matched positive control or benchmark against other anti-EGFR reagents. The IgG1 backbone also makes it useful for effector-function studies (ADCC/CDC) and as a starting scaffold for antibody-drug-conjugate or bispecific development. It is offered at low-endotoxin, research-grade purity (typically less than 1 EU/mg, with ultra-low-endotoxin options under 0.5 EU/mg) and in bulk milligram-to-gram quantities to support assay scale-up and standardization. It is not the clinical drug and is not for human or veterinary use. EGFR (epidermal growth factor receptor; ErbB1/HER1, UniProt P00533) is a single-pass transmembrane receptor tyrosine kinase and the founding member of the ErbB family. Ligands such as EGF, TGF-alpha, amphiregulin, and epiregulin bind the extracellular region and drive receptor homodimerization or heterodimerization with HER2, HER3, and HER4. Dimerization activates the intracellular kinase domain, leading to autophosphorylation of C-terminal tyrosines and recruitment of adaptors that trigger the RAS-RAF-MAPK, PI3K-AKT, and STAT pathways, promoting proliferation, survival, migration, and differentiation. EGFR is central to normal epithelial development but is frequently overexpressed, amplified, or mutated in cancers including colorectal, head and neck, lung, and glioblastoma, making it a heavily validated therapeutic and research target. Antibodies against its extracellular domain can block ligand binding and receptor activation.

Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, Epidermal growth factor receptor, ERBB, ERBB1, HER1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks